Long-term outcomes for adults with lupus at Peking University People's Hospital
Official title: A Prospective Cohort Study on Long-Term Outcomes in Patients With Systemic Lupus Erythematosus at Peking University People's Hospital
Run by Peking University People's Hospital · NCT07005479 · Data updated 2026-11-12
This project will follow adults with lupus at Peking University People's Hospital for up to 10 years to see how disease activity, organ involvement, achievement of Lupus Low Disease Activity State (LLDAS), and survival change over time.
Quick facts
| Study type | Observational |
|---|---|
| Ages | 18 Years and up |
| Sex | All |
| Enrollment | 1000 (estimated) |
| Sponsor | Peking University People's Hospital Academic / other |
| Drugs / interventions | prednisone |
| Locations | 1 site (Beijing, Beijing Municipality) |
| Status | Recruiting |
| Started | May 21, 2020 |
| Main results expected | May 20, 2030 |
| Study ends | May 20, 2032 |
| Registry record updated | June 5, 2025 |
| Trial ID | NCT07005479 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Adults (age 18 or older) diagnosed with SLE by ACR, SLICC, or EULAR/ACR criteria who can provide written consent are ideal candidates.
✕Probably not a fit
Children under 18, people unable to provide informed consent, and patients seeking immediate experimental therapies are unlikely to benefit directly from this observational follow-up.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This single-center, prospective observational cohort will enroll adults with SLE at Peking University People's Hospital and follow them for up to ten years. Regular visits will collect clinical assessments, laboratory tests, treatment histories, and patient-reported quality-of-life measures. Disease activity will be tracked using SLEDAI-2K and the study will record the frequency, duration, and determinants of achieving and maintaining Lupus Low Disease Activity State (LLDAS). Analyses will link LLDAS status, organ involvement, flare rates, treatments, and other factors with long-term survival and damage accrual in a Chinese patient population.
Why it matters
Potential benefit: If successful, findings could help doctors personalize treatment plans by identifying patterns and predictors of long-term disease control and survival in Chinese patients with lupus.
How similar studies have gone: Prior long-term lupus cohorts have shown that reaching and maintaining LLDAS is associated with reduced damage accrual and better survival, so this study builds on validated findings.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * All patients must meet at least one of the following classification criteria for Systemic Lupus Erythematosus (SLE): The 1997 American College of Rheumatology (ACR) Revised Classification Criteria; The 2012 Systemic Lupus International Collaborating Clinics (SLICC) Classification Criteria; The 2019 EULAR/ACR Classification Criteria for SLE. All patients must be over the age of 18 and competent to provide written consent. Exclusion Criteria: * Patients less than 18 years of age and patients who are unable to consent are excluded from the study.
Where it's running
-
Department of Rheumatology and Immunology, Peking University People's Hospital
Beijing, Beijing Municipality, China Recruiting
Study contacts
- Study coordinator: Haihong Yao, MD
- Email: yaohaihong@pku.edu.cn
- Phone: 010-88326666
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Effects of anifrolumab on arterial inflammation in SLE patients
This study tests whether anifrolumab can reduce blood vessel inflammation in people with active systemic lupus erythematosus.
-
Home urine testing for people with lupus
Participants with lupus will try weekly home urine tests in addition to usual care to see if this helps monitor kidney health over a year.
-
CR-402 treatment for refractory autoimmune disease
This study tests CRT-402, a CD19-targeted CAR-T therapy, in adults with active, treatment-resistant autoimmune diseases like SLE, systemic sclerosis, and inflammatory myopathy to see if it is safe and capable of helping control disease.
-
ATG-201 in adults with autoimmune diseases
This early, open-label study tests ATG-201 in adults with autoimmune diseases to see if it is safe and tolerable, and to get initial clues about how the body handles the drug and its effects.
-
Biomarker tests in adults with lupus to see how kidney disease changes over time
Researchers will follow adults with lupus to see if blood and urine biomarkers can predict kidney involvement, flares, and treatment responses during routine care.
-
Sirolimus added to standard therapy for adults with SLE-associated immune thrombocytopenia
This trial tests whether adding sirolimus to usual treatment helps adults with SLE-related immune thrombocytopenia see their platelet counts improve.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.